

105 CMR 720.000: LIST OF INTERCHANGEABLE DRUG PRODUCTS

Section

- 720.001: Purpose
- 720.002: Citation
- 720.010: Scope and Application
- 720.020: Definitions

Standards

- 720.040: Commission Review of Relevant Drug Products
- 720.050: List of Interchangeable Drug Products
- 720.060: Drug Products Excluded
- 720.070: Amendments to the Massachusetts List of Interchangeable Drugs

Procedures for Amending List of Interchangeable Drug Products

- 720.080: Procedures for Amending the Massachusetts List of Interchangeable Drugs
- 720.081: Petition to Amend List of Interchangeable Drug Products
- 720.082: Commission Review of Petition
- 720.083: Notice of Public Comment Period
- 720.084: Commission Recommendation of Amendments to Department
- 720.090: Department Adoption of Amendments
- 720.100: Severability
- 720.200: Appendix A: List of Interchangeable Drugs

720.001: Purpose

The purpose of 105 CMR 720.000 is to establish a drug formulary, or list of interchangeable drug products, for use by physicians, other practitioners, and pharmacists licensed to practice within the commonwealth, so that consumers of prescription drug products may realize cost savings by buying less expensive, safe drug products.

720.002: Citation

105 CMR 720.000 shall be known as the 105 CMR 720.000: *Massachusetts List of Interchangeable Drug Products*.

720.010: Scope and Application

105 CMR 720.000 establishes the list of interchangeable drug products from which a pharmacist must interchange a reasonably available less expensive drug product than that written, when a prescription written by a practitioner indicates "interchange". 105 CMR 720.000 also establishes criteria and procedures for inclusion of drug products on this list.

720.020: Definitions

The terms used herein shall have the meanings set forth below. Terms defined in M.G.L. c. 112, § 12D and c. 94C, § 1, and not defined herein shall have the meanings set forth therein when used in 105 CMR 720.000, unless the context clearly requires a different interpretation.

Bioequivalent Drug Products means drug products whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of therapeutic moiety under similar conditions. Some drug products may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered therapeutically equivalent because such differences in the rate of absorption are not essential to the attainment of effective body drug concentrations or are considered medically insignificant for the particular drug product studies.

720.020: continued

Drug products for which bioequivalence is considered essential are those whose bioinequivalence would have therapeutic significance, *i.e.* use of different brands of the same drug product or different batches of the same drug product would result in therapeutic failure or a hazard to the patient. This is most critical in a drug product that has a narrow therapeutic-toxicity range which requires careful patient titration and monitoring for safe and effective use.

Commissioner means the commissioner of public health appointed under M.G.L. c. 17, § 2.

Department means the Department of Public Health established under M.G.L. c. 17 as an agency within the Executive Department of the Commonwealth of Massachusetts.

Drug Product means a product which contains an active drug ingredient and is in a dosage form, *e.g.* tablet, capsule, or solution, generally, but not necessarily in combination with other substances included in the manufacturing process. An active drug ingredient is that portion of a drug product intended to produce a therapeutic effect.

FDA means the Food and Drug Administration of the United States Department of Health and Human Services.

Generic name means a non-proprietary (common) name used to identify a drug product as listed by the United States Adopted Names Council and the United States Pharmacopeia in the *USAN/USP Dictionary of Drug Names*.

Interchangeable Drug Product means a product containing a drug in the same amounts of the same active ingredients in the same dosage form as other drug products with the same generic or chemical name.

Pharmaceutically equivalent drug products means drug products which contain the same active ingredients, and are identical in strength or concentration, dosage form, and route of administration.

Public Health Council means the Department's governing body established under M.G.L. c. 17, § 3. *See also* M.G.L. c. 111, § 3.

Therapeutically equivalent drug products means drug products which are pharmaceutically equivalent; meet applicable standards for strength, quality, purity and identity; are bioequivalent in that:

- (a) they do not present a known or potential bioequivalence problem, and they do meet an acceptable in vitro standard; or
- (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standards matching both rate and extent of absorption; are adequately labeled; and are manufactured in compliance with current Good Manufacturing Practice regulations.

720.040: Commission Review of Relevant Drug Products

In preparing the List of Interchangeable Drug Products and amendments thereto, the Drug Formulary Commission shall determine whether drug products meet the standards set forth in 105 CMR 720.050. In making this determination, the Commission shall assess and evaluate pertinent data, including, but not limited to, the United States Pharmacopeia and its supplements, additional pertinent listings of the FDA, other state formularies, formularies of various hospitals of the commonwealth, and data submitted by manufacturers and other interested persons, including chemical and laboratory listing data and clinical evidence concerning bioequivalence and therapeutic equivalence where available. In reviewing this material, the Commission shall utilize the pharmaceutical and medical expertise of its members.

720.050: List of Interchangeable Drug Products

The Massachusetts List of Interchangeable Drug Products (MLID) shall consist of:

- (1) drug products which are considered by FDA to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name according to the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the United States Department of Health and Human Services;
- (2) drug products specified on a list established by the Department and set forth in 105 CMR 720.200, for which the Commission has determined that the bioequivalence is not essential, or if the Commission has determined that the bioequivalence may be essential, bioequivalence has been established. The list may include the following categories of drug products:
 - (a) drug products which hold New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) approved by the FDA, which FDA does not consider to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name; and
 - (b) drug products exempt from the Food, Drug and Cosmetic Act of 1962, and included in the Drug Efficacy Study Implementation (DESI) done by the National Academy of Sciences/National Research Council; and
 - (c) frequently prescribed drug products which were manufactured prior to 1938 and meet the FDA Good Manufacturing Practices Requirements; and
 - (d) frequently prescribed over-the-counter drug products which contain the same amounts of active ingredients, in the same dosage forms, as other drug products with the same general or chemical name.

720.060: Drug Products Excluded

The following categories of drug products are excluded from the list of interchangeable drug products:

- (a) drug products for which the Commonwealth has determined that bioequivalence may be essential, but for which bioequivalence has not been established; and
- (b) drug products which are the subject matter of patent rights issued by the U.S. Patent Office, for which provision by other than the patent-holder would violate the patent; and
- (c) drug products available from only one manufacturer at one price.

720.070: Amendments to the Massachusetts List of Interchangeable Drugs

- (1) Drug products which meet the criteria specified in 105 CMR 720.050(1) shall be deemed interchangeable and added to the Massachusetts List of Drugs upon publication by the United States Department of Health and Human Services of the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements.
- (2) Drug products which meet criteria specified in 105 CMR 720.050(2) shall be deemed interchangeable and added to the Massachusetts List of Interchangeable Drugs in accordance with procedures set forth in 105 CMR 720.080.

720.080: Procedures for Amending the Massachusetts List of Interchangeable Drugs

The Department, working with the Commission, shall review at least one a year and revise as necessary the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(2), and shall have the authority to review and revise the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(1) as necessary. The revisions to 105 CMR 720.050(1) shall be specified on an exception list established by the Department and set forth in 105 CMR 720.200. The revisions will add and delete drug products, based on current information concerning therapeutic efficacy and interchangeability of drug products.

720.081: Petition to Amend List of Interchangeable Drug Products

Any person who desires a drug product or products to be added to or deleted from the List of Interchangeable Drug Products, shall file a written petition with the Department to amend the List, pursuant to M.G.L. c. 30A, § 4. Each petition shall be in such form as the Department may require and shall be submitted to the Drug Formulary Commission.

720.082: Commission Review of Petition

Upon receipt of a petition, the Department shall submit the petition and the supporting information to the Commission for review. The Commission shall make a preliminary determination whether the List of Interchangeable Drug Products should be amended as proposed.

720.083: Notice of Public Comment Period

Upon completion of the review of all relevant information, including petitions, by the Commission, the Department shall propose amendments to the List of Interchangeable Drug Products by issuing a Notice of Public Comment Period pursuant to M.G.L. c. 30A, §§ 2 and 3. The Department shall mail a Notice of Public Comment Period to each person who filed a petition during the period ending 30 days before the Notice of Public Comment Period is issued. In addition, the Department shall mail a Notice of the Public Comment Period to each person who has filed a written request therefore with the Department during December of the previous year pursuant to M.G.L. c. 30A, § 2.

720.084: Commission Recommendation of Amendments to Department

Following the comment period Department staff shall review all evidence and commentary concerning the proposed amendments, and shall report its recommendation to the Commission. The Commission shall consider the staff recommendations, make such revisions as it deems appropriate, and shall recommend Amendments to the List of Interchangeable Drug Products for adoption by the Commissioner and the Public Health Council.

720.090: Department Adoption of Amendments

The Commissioner and the Public Health Council shall consider the recommendations of the Drug Formulary Commission, and shall adopt Amendments to the List of Interchangeable Drug Products.

720.100: Severability

The provisions of 105 CMR 720.000 are severable. If any provision shall be declared invalid by any court, such provision shall be null and void and such determination shall not affect or impair any of the remaining provisions.

REGULATORY AUTHORITY

105 CMR 720.000: M.G.L. c. 17, § 13; c. 112, § 12D.

720.200: Appendix A

MASSACHUSETTS
LIST OF
INTERCHANGEABLE DRUGS

Department of Public Health regulation 105 CMR 720.050 describes the *Massachusetts List of Interchangeable Drugs*.

105 CMR 720.050(a) calls for the automatic adoption of all "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements as published by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services. This publication is commonly referred to as the "*Orange Book*". It is reprinted by the U.S. Pharmacopeial Convention Inc. (USP) as *Volume III* of the *USP DI*.

105 CMR 720.050(b) allows for the establishment of the *Massachusetts Additional List of Interchangeable Drugs (Additional List)*, and provides the criteria upon which these drug products are approved.

All prescriptions written by generic name can be interchanged if the drug is multi-source. To determine if a prescription written for a brand name drug product is interchangeable in Massachusetts:

1. Look up the drug product by the brand name in the index or by generic name in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" ("*Orange Book*"). The drug products are arranged alphabetically.
2. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product in the "*Orange Book*".
3. If the same drug product, dosage form and strength has been assigned an "A" rating by FDA and is not listed on the *Exception List* contained within 105 CMR 720.050, the drug product is interchangeable.
4. If the drug product is not listed in the "*Orange Book*", refer to 105 CMR 720.050(b), the *Massachusetts Additional List of Interchangeable Drugs (Additional List)*.
5. Look up the drug product by the generic name in the *Additional List*. The drug products are arranged alphabetically.
6. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product listed on the *Additional List*.
7. If the same drug product, dosage form and strength are listed, the drug product is interchangeable.

Copies of the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements ("*Orange Book*") are available from the:

U.S. Food and Drug Administration
Department of Health and Human Services
Government Printing Office
Washington, D.C. 20402-9371
OPC 6768
(202) 783-3238
and www.fda.gov/cder/drug

720.200: continued

Copies of the *USP DI* (third volume of *USP DI* is the "*Orange Book*") are available from:

The United States Pharmacopeial Convention, Inc.,
12601 Twinbrook Parkway
Rockville, MD 20852
(301) 881-0666

Copies of the *Massachusetts Additional List of Interchangeable Drug Products* (document number 105 CMR 720.000) are available from:

The State House Bookstore
Room 116
Boston, MA 02133
(617) 727-2834
and [www.magnet.state.ma.us/dph/dcp/Drug Formulary/Drug Interchange](http://www.magnet.state.ma.us/dph/dcp/Drug%20Formulary/Drug%20Interchange)

720.200: continued

TABLE OF CONTENTS

Foreword

Introduction

Drug Product Problem Reporting Instructions

Exception List

Format of the *Additional List*

NDA, ANDA, Applicant (name) Changes

Abbreviations

Massachusetts Additional List of Interchangeable Drugs
(Alphabetical list of Official (Generic) Drug Names)

Partial Proprietary Brand Cross-reference

FOREWORD

The *Massachusetts List of Interchangeable Drugs*, is prepared by the Drug Formulary Commission (DFC) and the Department of Public Health. The DFC is comprised of nine men and women appointed by the Governor for the express purpose of developing a list of those drug products that are safely interchangeable -- that is, equivalent to each other in all significant respects. The DFC was established by M.G.L. c. 17, § 13. This law was enacted with the intent of saving money for consumers of prescription drugs, since drug products that are marketed under trademark or proprietary names are often available in the generic forms from competing manufacturers at substantially lower prices. M.G.L. c. 112, § 12D mandates prescription forms that allow practitioners to prescribe interchangeable drug products by simply signing the signature line. If a practitioner determines that a brand name drug product should be dispensed, he/she must sign the signature line and write the words "**no substitution**" in his/her own handwriting in the space provided below the signature line.

The regulations call for the automatic adoption of "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements (commonly referred to as the "*Orange Book*") as published by the U.S. Food and Drug Administration, Department of Health and Human Services, plus a list of additional drug products, the *Massachusetts Additional List of Interchangeable Drugs* ("*Additional List*"), individually reviewed and approved by the DFC and the Department. The regulations provide the criteria upon which the drug products listed on the *Additional List* are approved for interchange. The regulations also provide the DFC and the Department with the authority to review any "A" rated drug product listed in the "*Orange Book*" or drug product approved for interchange on the *Additional List* and delete it from the list of interchangeable drug products if deemed appropriate. Drug products assigned an "A" rating by FDA which are deleted from the *Massachusetts List* are placed on the *Exception List*. Drug products listed on the *Additional List* which are subsequently deleted are removed from the *Additional List*.

Of the many factors considered by the Commission in determining which drugs to include on the *List*, equivalent safety and effectiveness are paramount. The Commission reviews evidence on bioequivalence and pharmaceutical equivalence and includes on the *List* only those drug products determined to be fully interchangeable and whose manufacturers are approved by the U.S. Food and Drug Administration. Practitioners may prescribe any drug that appears on the *List* with confidence that it is as safe and effective as its brand name counterpart.

The efforts of the Commission in the assessment and evaluation of data and the preparation of the *List* are to be commended. The Department presents the *Massachusetts List of Interchangeable Drugs* with pride and with confidence that the *List* will greatly benefit consumers throughout the Commonwealth.

720.220: continued

INTRODUCTION

INTERCHANGEABLE (GENERIC) DRUG LAW

In 1976 the Massachusetts Legislature passed an Act Further Regulating the Establishment of a Formulary of Interchangeable Drug Products (St. 1976, c. 470, § 13), commonly known as the Generic Drug Law. This law, enacted to promote and regulate the use of generic drugs, created the Drug Formulary Commission to develop a list of interchangeable drug products and also required the use of a standard prescription form to encourage practitioners to prescribe generic drugs.

PRESCRIPTION FORM

M.G.L. c. 112, § 12D mandates prescription forms with one signature line. If the prescriber signs the prescription form and writes the words "**no substitution**" in his/her own handwriting in the space provided below the signature line, the pharmacist must fill the prescription exactly as indicated, with no interchange permitted. However, if the prescriber signs the prescription and does not write "**no substitution**" under his/her signature, the pharmacist is legally required to dispense a less expensive, equivalent interchangeable drug product listed in the *Massachusetts List of Interchangeable Drugs* if one is reasonably available.

MASSACHUSETTS LIST OF INTERCHANGEABLE DRUGS

The *Massachusetts List of Interchangeable Drugs* (MLID) consists of the "A" rated drug products listed in the "*Approved Drug Products with Therapeutic Equivalence Evaluations*" and its supplements as published by the U.S. Food and Drug Administration, Department of Health and Human Services ("*Orange Book*") and the *Massachusetts Additional List of Interchangeable Drugs* (*Additional List*). The *Additional List* is developed by the Drug Formulary Commission. The Commission determines drug products to be interchangeable only when they meet certain criteria:

- (a) the drug product is available from more than one source, with the same active ingredient in the same dosage form and strength;
- (b) its manufacturer is approved by the U.S. Food and Drug Administration (FDA); and
- (c) when essential to therapeutic outcome, the manufacturer of the drug has documented clinical evidence of bioequivalence.

The Commission judges that all the drugs included on the MLID meet these standards and are bioequivalent, if essential, based on assessment and evaluation of the U.S. Pharmacopeia and its supplements, other state and hospital formularies, listings of the U.S. Department of Health and Human Services of the FDA, and on the expertise of its members.

The *List* does not include:

- (a) drugs that are protected by patent rights or available from only one source;
- (b) many controlled-release and enteric coated drug products since they may not consistently deliver the same quantities of their active ingredients;
- (c) those drugs for which the Commission had any significant doubt about safe interchange between manufacturers; and
- (d) any drug for which bioequivalence is considered essential but for which bioequivalence has not been demonstrated or an appropriate standard for bioequivalence has not been established.

Bioequivalence is determined to be necessary for a particular drug when bioinequivalence might result in therapeutic failure or hazard to the patient. Bioequivalent drug products do not show a significant difference in the rate and extent of absorption when administered at the same dosage under similar conditions. Drugs that are equivalent in the extent to which they are absorbed into a patient's body that differ in the rate of absorption may be therapeutically equivalent -- having the same medical effect -- either because the rate of absorption is not essential to the attainment of effective body concentrations of the drug, or because the difference in the rate is otherwise considered medically insignificant. Bioequivalence is a primary

720.220: continued

consideration for those drug products with a narrow therapeutic/toxic dosage range (when variation in the rate or extent of absorption could have a critical effect) where careful determination of the correct dosage and monitoring of the patient is essential to safe and effective use. To determine for which drugs bioequivalence is essential, the Commission relies on expert medical testimony, studies done by the pharmaceutical industry, the knowledge and expertise of the individual members of the Commission, and advice from the FDA.

All drug products manufactured by FDA approved firms are considered safe and effective for their intended use, even if the product has not been included in the MLID. A practitioner may begin a patient's therapy with a drug product from any manufacturer who has been approved by the FDA, even though interchange of the drug once the dosage has been calculated for the individual is not advised.

Several generic drug products are manufactured under the same new drug application (NDA) as the brand name drug products. According to section 1.6 of the *Orange Book*, drug products with the same NDA are therapeutically equivalent. Massachusetts regulations allow the interchange of these products. Distributors or repackagers of drug products manufactured under the same NDA as the brand name product are not identified in the *Orange Book*. Pharmacists who may not be able to determine if drug products are interchangeable should contact the manufacturers, distributors or repackagers. In addition the Department maintains an unofficial list of these products.

Information relative to the Interchangeable (Generic) Drug Law may be obtained from the Department of Public Health, Division of Food and Drugs, 305 South Street, Jamaica Plain, MA 02130, telephone number (617) 727-2670, and from the Boards of Registration in Medicine, Dentistry and Pharmacy.

DRUG PRODUCT PROBLEM REPORTING INSTRUCTIONS

Since 1971 the United States Pharmacopeia (USP), in cooperation with various professional associations and the Food and Drug Administration (FDA), has operated the *Drug Product Problem Reporting Program*. This program can be utilized by pharmacists, physicians, or consumers to report any product problems encountered when using drugs interchanged under the Massachusetts generic drug law. The program is product oriented, and patient identification not requested. Should you prefer to remain anonymous, so indicate to the USP and your name will be withheld from the manufacturer and the FDA. Your participation in reporting problems will help to ensure that the drug products prescribed and dispensed in Massachusetts are of continued high quality.

Reports should be sent to The United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, (301) 881-0666. The USP is an impartial, non-governmental organization concerned with drug standards and quality control. After USP receives a report, copies are forwarded to the FDA and to the manufacturer of the product involved. Either the FDA or the manufacturer may act to investigate or correct problems.

EXCEPTION LIST

Orange Book "A" rated drug products not approved for interchange.

There are currently no products designated to be listed on the Exception List.

ADDITIONAL LIST

The *Massachusetts Additional List of Interchangeable Drugs (Additional List)* has been printed in a format designed to be concise and understandable. Interchangeable drugs are listed alphabetically according to their official (chemical or generic) names, and separate sections in each listing show dosage forms, strengths, FDA approved manufacturers, and categories.

720.220: continued

DRUG

Drugs are listed in alphabetical order by their generic names and are printed in capital letters. Drug products containing more than one active ingredient (for example, CODEINE PHOSPHATE, GUAIFENESIN) are listed in the conventional order of ingredients.

Only drug products grouped under single headings are to be interchanged.

DOSAGE FORM

Under the generic names are listed the various multisource dosage forms in which a drug product is available. Abbreviations used for dosage forms and approved manufacturers are found in the front of the *Additional List*.

Only identical dosage forms and strengths of identical drugs are to be interchanged.

STRENGTH

The approved strengths of the drug products are listed under the heading "Strength(s)." The "strengths" must be read along with the "dosage forms" since any strength shown is available only for the dosage form directly to its left. Dosage strength is in metric units that are sometimes rounded off from apothecary measures, which may introduce slight variations in the strength of certain products. Single ingredient drug product strengths are separated by commas. Combination drug products have a slash separating the strengths of the individual ingredients. If more than one strength of a single component of a combination drug product is approved, they will be separated by commas. For example, the strength of a tablet of aspirin with codeine phosphate is "325mg / 15mg, 30mg, 60mg" which means that the combination is available with 325 milligrams of aspirin and 15, 30, or 60 milligrams of codeine phosphate. Drug products with three or more components have their active ingredients listed individually in parentheses and have slashes separating the strengths of the individual ingredients.

MANUFACTURERS

Next to the heading "Manufacturers" are all approved manufacturers for the drug product in that group, listed by three letter abbreviations in capital letters. (See list of manufacturer abbreviations in front of the *Additional List*.) Listed manufacturers have met all legal requirements, including compliance with the FDA Good Manufacturing Practices for the production of the drug product indicated. Approved manufacturers hold current new drug applications (NDAs) or abbreviated new drug applications (ANDAs) when required by law.

NDA, ANDA APPLICANT (NAME) CHANGES

Because it is not practical to identify in the *Massachusetts Additional List of Interchangeable Drugs (Additional List)* each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, these transfers and name changes are identified in this section. In addition, the new manufacturers are listed in parenthesis beside the original manufacturer under the *Manufacturers' Abbreviations* section of the *Additional List*. Where only partial approved product lines are transferred between applicants, each approved product involved will appear with the manufacturer name change in the *Additional List* amendment.

Previously listed name changes have been incorporated into the revised Manufacturers' Abbreviations section.

ABBREVIATIONS

The following abbreviations are used in the *Massachusetts List of Interchangeable Drugs*.

720.200: continued

DOSAGE FORMS

aero	aerosol	ml	milliliter
amp	ampule	oint	ointment
cap	capsule	ophth	ophthalmic
conc	concentrate	oral gran	oral granules for
e.c.	enteric-coated		reconstitution
elix	elixir	oral powder	oral powder for
g	gram		reconstitution
Hbr	hydrobromide	oral sol	oral solution
HCl	hydrochloride	pow	powder
HC	hydrocortisone	sol	solution
inhl	inhalation	SR	sustained release
inhl liquid	inhalation liquid	subl tab	sublingual tablet
inhl sol	inhalation solution	supp	suppository
inj	injection	susp	suspension
irr sol	irrigating solution	syr	syrup
I.U.	international units	tab	tablet
liq	liquid	top aero	topical aerosol
lot	lotion	top swab	topical swab
mcg	microgram	U	units
mEq	milliequivalents	vag	vaginal
mg	milligram		

MANUFACTURERS' ABBREVIATIONS

3MP	3M Pharmaceutical	APK	Apothekernes
AAA	Alpha Therapeutic	APP	American Pharmaceutical Partners
ABB	Abbott		Inc
ABI	Abic	ARC	Arcola Labs.
ABL	Able Laboratories	APC	Arcum Pharmaceuticlal Corp.
ACI	ACIC Limited	ARP	Armenpharm
ACP	Advanced Care Prod.	ARM	Armour Pharmaceuticals
ADV	Advanced Remedies	ASC	Ascot Hospital Products
AGV	Agvar Chemicals	ASA	Asta
AKO	Akorn	ASP	Astra Pharmaceuticals LP
AKZ	Akzona Inc.	ATH	Athena Neurosciences
ALC	Alcon Labs	BAK	Baker Norton
ALL	Allergan Pharmaceuticals	BAN	Banner Pharmacaps
ALI	Alliance Pharmaceutical	BAP	Barlan Pharmacal
ALP	Alpharma	B/I	Boehringer Ingelheim
APP	Alphapharm Party	B/M	Boehringer Mannheim. Ther. Div
ALT	Altana	BAR	Barr Labs
ALZ	Alza Corp.	BAS	Basel Pharmaceuticals
ALR	Alra Laboratories	BAT	Bartor
AMA	Amaric	B&L	Bausch & Lomb
AMB	Ambix Labs	BAY	Bayer Corp
ACC	American Cyanamid Co.	BEA	Beach Prod.
AHP	American Home Products	B-D	Becton,Dickinson & Co.
ARL	American Regent Labs.	BED	Bedford Laboratories
AME	Amersham	BEL	Bell
AMG	Amgen	BDP	Beta Derm Pharmaceuticals
AMI	Amide Pharmaceuticals	BER	Berlex
AMT	American Therapeutics	BFA	B.F. Asher
ANA	Anabolic	BHC	B.H. Chemicals
ANB	Anbex	BID	Biodevelopment
ANC	Angus Chemical	BIO	Bio Technology General
ANE	Anesta	BIV	Biovail
ANG	Angelini	BLA	Blairex Laboratories
APO	Apothecon	BLO	Block Drug Co.

720.200: continued

BLU	Bluline	DHL	DHL Laboratories
BRL	Blue Ridge Laboratories	DIA	Dial Corp.
BOC	Bock Pharmacal	DIS	Dista
BOW	Bowman Pharm.	DMD	Duramed
BMS	Bristol Myers Squibb	DMG	D M Graham Laboratories
BRC	Bracco Diagnostics	DOW	Dow Pharmaceutical
BRD	Bradley Pharm.	DPT	Dupont Pharmaceuticals
BRA	Braintree Laboratories	DPM	Dupont Merck
BRI	Bristol-Myers Prod.	DUR	Dura Pharmaceuticals
BTG	BTG Pharmaceuticals	DUN	Dunhall
BVL	Ben-Venue Labs	DYN	Dynapharm
BYR	Byron Chemical	E/K	Eastman Kodak
C&M	C & M Pharmacal	EAT	Eaton Medical Corp.
CAD	Cadema Medical Products	ECR	ECR Pharmaceuticals
CAG	Calgon Corp.	ELA	Elan Pharmaceuticals
CDC	Carderm Capital	ELL	Ellis Pharmaceuticals
C-P	Chesebrough - Ponds	EMP	EM Pharma
C-W	Cook - Waite	END	Endo
C/C	Chase Chemical	EON	Eon Laboratories
CSL	Chase Laboratories	ENQ	Enquay Pharm
C/P	Corvit Pharmaceuticals	ENZ	Enzon
CAL	Carlisle	ESR	Elkins-Sinn/AH Robins
CAM	Camall	ERS	Ersana
CAR	Carnick Labs	ESI	ESI Lederle Generics
CTW	CarterWallace	ESP	ESI Pharmacal
CEN	Century Pharmaceuticals	ETH	Ethicon Inc.
CBV	Cetus Ben Venue Therapeutics	ETX	Ethex
CHA	Chamberlin Parenteral Corp.	ETK	Ethitek Pharmaceuticals
CHE	Chelsea Laboratories	EVY	Everylife
CHM	Chemed Corp.	EZC	E Z EM Co.
CVO	Ciba Vision Ophthalmics	FAU	Faulding Pharm. Co.
CIR	Circa Pharmaceuticals	FER	Ferndale
CJD	Copanos, J.D.	FRT	Ferrante
CLA	Clay - Park	FRR	Ferring Labs
CLO	Clonmel Healthcare	FIS	Fisons
CMB	C.M. Bundy	FLE	Fleming & Co.
CMC	Consolidated Midland Corp.	FOR	Forest
C/T	Controlled Therapeutics	FOU	Fougera
CMP	Carolina Medical Products	FOY	Foy
CNC	H.R. Cenci	FRE	Fresenius
COL	Colgate Palmolive	G&W	G & W
COM	Combe	GAL	Galderma
CON	Connaught Laboratories	GEI	Geigy
COO	Cooper Labs	GEC	Gencon
COP	Copley Pharmaceutical	GED	Genderm
CPG	Consolidated Pharmacy Group	GET	Genentech
CRE	Creighton Products	GEP	Genpharm
CUM	Cumberland Swan	GEV	Geneva
CUR	Curatex Pharmaceuticals	GES	Gensia Sicor Pharmaceuticals Inc
CTL	Central Pharmacal	GEZ	Genzyme
D&G	Davis & Geck	GIL	Gilbert Laboratories
D/L	DPT Laboratories	GLD	Glades
D-R	Del-Ray Laboratories Inc.	GLW	GlaxoWellcome
DAN	Danbury Pharmacal	GLE	Glenwood
DAR	Darby Group Companies	GLO	Global Pharm.
DEL	Dell	G/P	Golden Pharms.
DEP	Deproco	GOL	Goldine
DER	Dermik Laboratories	GRE	Greenstone
DES	Deseret Medical	GRI	Griffen,KW
DEY	Deylabs	G/L	Gruppo Lepetit

720.200: continued

GUA	Guardian	LAF	Lafayette Pharms
GYM	GYMA Laboratories	LAN	Lannett
GYN	Gynopharm	LED	Lederle
H-R	Holland-Rantos	LEI	Leiras
HAL	Halsey Labs	LEK	Lek Ljubliana
HAM	Hamilton Pharmaceuticals	LEM	Lemmon
HAN	Hnford GC	LEO	Leo Pharms
HEA	Heather	LIF	Life Labs
HEN	Heran Pharmaceutical	LIL	Lilly
HEX	Hexcel Chemical Products	LIP	Liposome
HER	Hermal Pharmaceutical	LIQ	Liquipharm
HIC	Hickam	LNK	LNK International
H/D	Hill Dermaceuticals	LOC	Loch Pharmaceuticals
HIR	Hirsch Industries	LOR	Lorex
HIT	Hi Tech Pharma	LOT	Lotus Biochemical
HTP	High Technology Pharmacal	LPI	LPI Holding
HLC	Halocarbon	LUI	Luitpold
HCC	Hoechst Celanese Corp.	LUS	Lek USA Inc.
HMR	Hoechst Marion Roussel	LYN	LYNE Laboratories
HOE	Hoechst-Rousel	M/P	Mallinckrodt Pharmaceutical.
HOR	Horus Therapeutics	MAY	Mayrand
HOY	Hoyt	MAT	Matrix Labs
HUD	Hudson Pharmaceuticals	MCG	McGaw
HUN	Huntington	MCN	McNeil Consumer Products
HYB	Hybritec Inc.	MDP	MD Pharmaceuticals
HYG	Hygenics	MEA	Mead Johnson
HYR	Hyrex	MJN	Mead Johnson Nutritionals
IMM	Immunex	M/R	Medco Research
IMP	IMP Inc.	MVA	Medeva
ICN	ICN Pharmaceuticals	MEP	Medics Pharmaceuticals
IMS	International Medication	MPI	Medi Physics, Inc.
INP	Interpharm	MAG	Mepha AG
INV	Invamed, Inc.	MER	Mericon
INW	Inwood Labs	MET	Metronic
ICC	Interchem Corp.	MGI	MGI Pharma
ILC	International Latex Corp.	MID	Midway Medical
ING	Ingram Pharmaceutical	MIK	Mikart Laboratories
INH	Inhalon	MIS	Mission Pharmacol
IOL	Iolab	MJP	MJ Pharmaceuticals
IOM	Iomed	MKL	Moore Kirk Labs
IPR	IPR Pharm	MLI	Marchar Laboratories
IVA	IVAX	MLP	Miller Pharmacal
J&J	Johnson & Johnson	MLX	Milex
JAC	Jacobus	MMD	Marion Merrell Dow
JAN	Janssen Pharmaceuticals	MOR	Morton Grove
JER	Jerome Stevens Labs	MCK	Merck & Co.
JRW	Johnson RW	MSM	Marsam
JON	Jones Pharma Inc	MSL	Marshall Pharmacal
KAL	Kalapharm	MTC	Martec
KBP	Kabi Pharmacia	MOV	Mova
KEE	Keene	MUR	Muro
KED	Kendall	MUT	Mutual Pharmaceuticals
KEN	Kenwood	MYL	Mylan Pharmaceuticals
KIN	King Pharmaceuticals	NEP	Nephron Pharmaceuticals Inc
KIR	Kirkman Sales	NEU	Neutrogena
KNO	Knoll	NOR	Norbrook Laboratories
KPI	Key Pharmaceuticals	N/W	Norton Waterford
KVP	KV Pharmaceutical Co.	N/N	Novo Nordisk
L/F	Labs Fournier	NEW	Newtron Pharmaceuticals
L/A	Laboratories Atral	NHN	Norton HN

720.200: continued

NOV	Novocol	RAC	Rachelle Labs
NVP	Novopharm Ltd.	REN	Ren-Pharm Internatl. Ltd.
NUM	Numark	RHP	Rhone - Poulenc
NYC	Nycomed	RPR	Rhone-Poulenc Rorer
NYL	Nylos Trading	RAH	Robins, A.H.
ORI	Organon, Inc.	REX	Rexall/Sundown
OCL	Oclassen	RIC	Richlyn Labs
OHM	OHM Laboratories	ROC	Roche Labs.
OMD	Ohmeda Pharmaceutical	RPF	Roerig/Pfizer
OSA	On Site Azla	ROA	Roaco
ODC	Ormont Drug & Chemical	RBP	Roberts Pharmaceutical
OPC	Ortho Pharmaceuticals	ROR	Rorer
OPT	Optopic Laboratories Corp.	ROS	Ross Labs
ORG	Organics	ROX	Roxane Labs
OAP	Otsuka America Pharmaceutical	ROY	Royce Laboratories
PAK	Pal-Pak	RPC	Rosemont Pharmaceutical Corp.
PAL	Palisades	RUG	Rugby Labs
P/D	Parke Davis	S-M	Spencer-Mead
P/I	Plantex/Ikpharm	S/W	Sanofi Winthrop
P/K	Purepac-Kalipharma	S/L	Schmid Laboratories
P/P	Parmed Pharmaceuticals	SAK	Sankyo
PAC	Paco Research	SAV	Savage Labs/Altana
PAD	Paddock Labs	SAN	Sandoz
PHD	Pharmaderm	SCE	Scherer, R.P.
PAN	Panray	SPI	Schein Pharmaceutical, Inc.
PAR	Par	SCH	Schering Corporation
PNL	Parnell	S/P	Schering/Plough
PER	Perrigo	SWZ	Schwarz Pharma
PCE	Pharmachemie	SZG	SchwarzGMBH
PHC	Pharmics	SCI	ScinoPharm International
PHK	Pharmakinetics Labs	SCS	SCS Pharmaceuticals
PHM	Pharmeral	SEA	Searle
PHO	Phoenix Labs	SER	Serono Laboratories
PHS	Pharma Serve	SEQ	Sequus Pharmaceuticals
PHT	Pharmaton	SHM	Sherwood Medical
PFF	Pfeiffer	SHI	Shionogi USA
PFI	Pfizer	SID	Sidmak Laboratories
P/U	Pharmacia & Upjohn	SIG	Sigma Tau
P/A	Pharmaceutical Association	SIX	Silarx
PIO	Pioneer Pharmaceutical Inc.	SKB	Smith, Kline Beecham
PPI	Physicians Products Inc.	SBH	Sola Barnes Hind
PSA	Pharmaceutical Specialist Assoc	SOL	Solopak Laboratories
POH	Pohl Boskamp	SLV	Solvay
POL	Polymedia	SOM	Somerset
PGP	Prographarm	SBM	Sorin Biomedics
PRD	Professional Disposables	SDP	Sperti Drug Products
PRO	Proter Laboratory	STI	Steifel
PRI	Private Formulations	STL	Stanlabs Pharmaceutical Co.
P&G	Proctor & Gamble	STR	Star Pharmaceuticals
PRV	Pharmavite	STS	Steris Laboratories
PTK	Pharma-Tek	STZ	Storz Ophthalmics
PUF	Purdue Frederick	SUP	Superpharm
PUR	Purepac	SPP	Suppositoria
QUA	Quantum Pharmics Ltd.	SUR	Survival Technology
QLT	QLT PhototherapeuticsInc.	SYN	Syntex
RAN	Ranbaxy Pharmaceuticals	SYO	Syosset Labs
R/C	Reckitt & Colman	TAB	Tablicaps
R&C	Reed & Carnrick	TAG	Tag Pharmaceuticals
R/I	Research Industries	TAK	Takeda
RXP	Rexar Pharmacal	TAP	Tap Holdings

720.200: continued

TAR	Taro Pharmaceutical	W-A	Wyeth Ayerst
TAY	Taylor Pharmaceuticals	W-C	Warner-Chilcott
TEC	Technilab	WAW	Warner Wellcome
THE	Theratech	WRR	Warrick Pharm
THK	Therakos	WEP	WE Pharmaceuticals
THA	Thames Phamacol Co. Inc.	WEN	Wendt Laboratories
TIC	Tican Pharmaceuticals	WPP	West Point Pharma
TOP	Topiderm	WES	Westwood Squibb Pharmaceuticals
T/L	Torch Laboratories	W-W	West-Ward
TOR	Torigian Lab	W/L	Wharton Labs
UDL	UDL Laboratories	WBY	Whitby
UMD	Unimed	WWT	Whiteworth Towne
UPJ	Upjohn	WAL	Wallace Labs
USL	Upsher-Smith Labs	WAR	Warner-Lambert
VAL	Vale Chemical	WAT	Watson Laboratories
VAN	Vangard	WOC	Wockhardt
VES	Vestal	XTT	Xttrium Laboratories
VIC	Vicks Pharmacy Products	YAM	Yamanouchi
VIN	Vintage	YOS	Yoshitomi Laboratories
VIR	Viratek	ZCA	Zeneca
VIS	Vistakon, Inc.	ZGP	Zenith Goldline Pharmaceuticals
VIV	Vivan Pharmacal		

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

AMINOPHYLLINE, EPHEDRINE Hcl			
Dosage form(s):	TABLETS	Strength(s):	130mg/25mg
Manufacturers:	STL		
Category:	OTC		
AMYL NITRITE			
Dosage form(s):	INHALATION	Strength(s):	0.3ml
Manufacturers:	GLW, CMC		
Category:	PRE-38		
ASPIRIN W/ CODEINE PHOSPHATE			
Dosage form(s):	TABLET	Strength(s):	325mg/15mg, 30mg, 60mg
Manufacturers:	BAR, GLW, CHE, GEV, HAL, P/D, ZGP		
Category:	PRE-38		
ATROPINE SULFATE			
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s):	0.5%, 1%, 2%
	OPHTHALMIC OINTMENT		0.5%, 1%
Manufacturers:	ALC, ALL, ESR, FOU, INV, MUR, B&L, STS, SUR		
Category:	PRE-38		
ATROPINE SULFATE COMPOUND (ATROPINE SULFATE, SCOPOLAMINE HBr, HYOSCYAMINE SULFATE, PHENOBARBITAL)			
Dosage form(s):	TABLET	Strength(s):	0.0194mg/0.0065mg/
	0		1037mg/16.2mg
Manufacturers:	ALL, CHE, M/P, MAY, TAY, RAH, WES		
Category:	DESI		
BENZOCAINE, ANTIPYRINE			
Dosage form(s):	OTIC SOLUTION	Strength(s):	1.4%, 5.4%
Manufacturers:	AMB, W-A, CLA, RPC, S-M, THA		
Category:	PRE-38		
BENZOYL PEROXIDE			
Dosage form(s):	GEL	Strength(s):	2.5%, 5%, 10%
Manufacturers:	BMS, CLA, GAL, STI, SYO, VIC, WES		
Category:	OTC		
BENZTHIAZIDE			
Dosage form(s):	TABLET	Strength(s):	50mg
Manufacturers:	GEV, PFI, RAH,		

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Category:	B	
BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBr, PSEUDOEPHEDRINE HCl		
Dosage form(s):	SYRUP	Strength(s): 2mg/10mg/30mg/5ml
Manufacturers:	RAH, RPC	
Category:	OTC	
BROMPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE, GUAIFENESIN COMBINATION		
Dosage form(s):	SYRUP	Strength(s): 4mg/5mg/5mg/100mg/5ml
Manufacturers:	HAL, LIF, RAH, RPC,	
Category:	OTC	
CAFFEINE AND SODIUM BENZOATE		
Dosage form(s):	INJECTION	Strength(s): 250mg/ml
Manufacturers:	TAY	
Category:	PRE-38	
CALCIUM GLUCONATE		
Dosage form(s):	INJECTION	Strength(s): 10%
Manufacturers:	ARL, APC, APP, CMC, CEN, BAY, ESR, GEN, HYR, KIR, LAN, LIL, M/P, P/D, RIC, STL, P/U ,	
Category:	PRE-38	
CARBINOXAMINE MALEATE, PSEUDOEPHEDRINE HCl, DEXTROMETHORPHAN HBr		
Dosage form(s):	DROPS	Strength(s): 2mg/25mg/4mg/ml
	SYRUP	4mg/60mg/15mg/5ml
Manufacturers:	ALP, ROS	
Category:	PRE-38	
CHLORAL HYDRATE		
Dosage form(s):	CAPSULE	Strength(s): 500mg
	SYRUP	250mg/5ml, 500mg/5ml
Manufacturers:	BMS, C/C, ALP, PHC, PUR, ROX, SCE, , ZEN	
Category:	PRE-38	
CHLORDIAZEPOXIDE W/ CLIDINIUM BROMIDE		
Dosage form(s):	CAPSULE	Strength(s): 5mg/2.5mg
Manufacturers:	BAR, CHE, EON, GEV, HAL, ROC, LEM, PAR, QUA, ZGP	
Category:	DESI	
CHLOROTHIAZIDE W/ RESERPINE		
Dosage form(s):	TABLET	Strength(s): 250mg/0.125mg, 500mg/0.125mg
Manufacturers:	MCK, MYL,	
Category:	B	
CHLORPHENIRAMINE MALEATE		
Dosage form(s):	TABLET	Strength(s): 4mg, 8mg, 12mg
	SYRUP	2mg/5ml
Manufacturers:	LAN, SCH	
Category:	OTC	
CHOLINE MAGNESIUM TRISALICYLATE (CHOLINE SALICYLATE, MAGNESIUM SALICYLATE)		
Dosage form(s):	TABLET	Strength(s): 500mg (=293mg/362mg), 750mg (=440mg/544mg), 1000mg (=587mg/725mg)
Manufacturers:	PUF, SID	
Category:	PRE-38	
CODEINE PHOSPHATE		
Dosage form(s):	INJECTION	Strength(s): 15mg, 30mg, 60mg/ml
Manufacturers:	ESR, KNO, STL, W-A	
Category:	PRE-38	
CODEINE PHOSPHATE /GUAIFENESIN LIQUID		
Dosage form(s):	LIQUID	Strength(s): 10mg/100mg/5ml
Manufacturers:	RAH, HAL	
Category:	PRE-38	

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

CYANOCOBALAMIN		
Dosage form(s):	TABLET	Strength(s): 10mcg, 25mcg,
	CAPSULE	50mcg, 100mcg, 250mcg
Manufacturers:	APP, BER, BMS, STS, DEL, ESR, INV, LEM, LIL, MMD, MCK, ALP, ORI, P/D, SAV, SOL, P/U, W-A	
Category:	OTC	
CYCLANDELATE		
Dosage form(s):	CAPSULE	Strength(s): 200mg/400mg
Manufacturers:	CHE, GEV, DAN, FOR, INW, W-A, LAN, LEM, MDP, PAR, PIO, ZGP	
Category:	DESI	
DEXAMETHASONE		
Dosage form(s):	TABLET	Strength(s):0.25mg, 0.5mg, 0.75mg, 1.5mg, 4mg
Manufacturers:	GEV, DAN, MCK, MYL, ORI, PAR, PRI, RIC, SLV, ROX, , USL	
Category:	B	
DIETHYLPROPION HCl		
Dosage form(s):	TABLET	Strength(s): 25mg
	SUSTAINED RELEASE TABLET	75mg
Manufacturers:	CAM, , LEM, MMD, MDP, 3MP	
Category:	B	
DIETHYLSTILBESTROL		
Dosage form(s):	TABLET	Strength(s): 0.1mg, 0.5mg, 1.5mg
	VAGINAL SUPPOSITORIES	
Manufacturers:	BMS, LIL	
Category:	B	
DIGOXIN		
Dosage form(s):	TABLET	Strength(s): 0.125mg, 0.25mg, 0.5 mg
Manufacturers:	GLW, AMI	
Category:	PRE-38	
DIGOXIN		
Dosage form(s):	INJECTION	Strength(s): 0.25mg/ml, 0.5mg/2ml
Manufacturers:	GLW, ESR, EON, W-A	
Category:	PRE-38	
DIMENHYDRINATE		
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	ANA, STS, CHE, GEV, ESR, LEM, SEA, , W-A	
Category:	OTC	
DIPHENHYDRAMINE HCl		
Dosage form(s):	CAPSULE	Strength(s): 25mg, 50mg
	ELIXIR	12.5mg/5ml
Manufacturers:	HAL, ICN, P/D	
Category:	OTC	
DISULFIRAM		
Dosage form(s):	TABLET	Strength(s): 250mg, 500mg
Manufacturers:	W-A, DAN	
Category:	B	
EPINEPHRINE HCl		
Dosage form(s):	INJECTION	Strength(s): 0.01%, 0.1%
	OPHTHALMIC SOLUTION	0.1%, 0.25%, 0.5%, 1%, 2%
Manufacturers:	ABB, ALC, ALL, ARL, ESR,IMS, INV, LAN, P/D, W-A	
Category:	PRE-38	
ESTROGENS, ESTERIFIED		
Dosage form(s):	TABLET	Strength(s): 0.3mg, 0.625mg, 1.25mg, 2.5mg
Manufacturers:	BMS, PRI, SLV, SKB, SYN	
Category:	B	
ETHAVERINE HCl		
Dosage form(s):	CAPSULE	Strength(s): 100mg

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	TABLET	
Manufacturers:	BFA, KEN, LEM, MEP	
Category:	PRE-38	
ETHINYL ESTRADIOL		
Dosage form(s):	TABLET	Strength(s): 0.02mg, 0.05mg
Manufacturers:	ORI, SCH, P/U	
Category:	B	
FLUOXYMESTERONE		
Dosage form(s):	TABLET	Strength(s): 2mg, 5mg, 10mg
Manufacturers:	BMS, RPC, P/U	
Category:	B	
GLYBURIDE		
Dosage form(s):	TABLET	Strength(s): 1.25mg, 2.5mg, 5mg
Manufacturers:	HOE, P/U	
Category:	B	
HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE		
Dosage form(s):	TABLET	Strength(s): 25mg/15mg/0.1mg
Manufacturers:	DAN, GEI, LEM	
Category:	B	
HYDROCHLOROTHIAZIDE W/ RESERPINE		
Dosage form(s):	TABLET	Strength(s): 25mg/0.125mg, 50mg/0.125mg, 25mg/0.1mg, 50mg/0.1mg
Manufacturers:	KNO, CAM, GEI, GEV, DAN, LEM, MCK, PUR, ZGP	
Category:	B	
HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE		
Dosage form(s):	SYRUP	Strength(s): 5mg/25mg/5ml
Manufacturers:	DPT, ALP, RPC	
Category:	OTHER	
HYDROCORTISONE, IODOCHLORHYDROXYQUIN		
Dosage form(s):	CREAM	Strength(s): 0.5%, 1% / 3%
	OINTMENT	
Manufacturers:	AMB, ALT, CLA, DER, BAY, DUR, GEI, LEM, ALP, SLV, THA,	
Category:	DESI	
HYDROFLUMETHIAZIDE, RESERPINE		
Dosage form(s):	TABLET	Strength(s): 25mg, 50mg/0.125mg
Manufacturers:	APO, RPC, ZGP	
Category:	B	
HYDROQUINONE 4% CREAM		
Dosage form(s):	TOPICAL CREAM	Strength(s): 4%
Manufacturers:	ICN, ETX	
Category:	PRE-62	
HYDROQUINONE CREAM 4%		
Dosage form(s):	CREAM	Strength(s): 4%
Manufacturers:	ICN; GLD	
Category:	PRE-1962	
HYDROQUINONE 4% CREAM with SUNCREENS		
Dosage form(s):	TOPICAL CREAM	Strength(s): 4%
Manufacturers:	ICN, ETX	
Category:	PRE-62	
HYDROQUINONE CREAM 4% with SUNCREEN		
Dosage form(s):	CREAM	Strength(s): 4%
Manufacturers:	ICN; GLD	
Category:	PRE-1962	
HYDROQUINONE TOPICAL SOLUTION		
Dosage form(s):	TOPICAL SOLUTION	Strength(s): 3%
Manufacturers:	NEU, GLD	

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Category:	PRE-38
-----------	--------

720.200: continued

NON-TEXT PAGE

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

ISOSORBIDE DINITRATE	Dosage form(s): SUSTAINED RELEASE CAPSULE	Strength(s): 40mg
	Manufacturers: ASC, GEV, FOR, W-A, SUP	
	Category: B	
ISOXSUPRINE HCl	Dosage form(s): TABLET	Strength(s): 10mg, 20mg
	Manufacturers: GEV, MEA	
	Category: PRE-38	
L-HYOSCYAMINE SULFATE	Dosage form(s): TABLET	Strength(s): 0.125mg
	Manufacturers: BFA, GLW, SWZ	
	Category: PRE-38	
LEVODOPA	Dosage form(s): TABLET	Strength(s): 250mg, 500mg
	CAPSULE	100, 250, 500mg
	Manufacturers: ROC, P&G	
	Category: B	
MAGNESIUM SALICYLATE	Dosage form(s): TABLET	Strength(s): 600mg
	Manufacturers: BFA, END, RBP, MLP, ,	
	Category: OTHER	
MAGNESIUM SULFATE	Dosage form(s): INJECTION	Strength(s): 10%, 12.5%, 50%
	Manufacturers: ABB, APP, ARL, CMC, ESR, IMS, LIL	
	Category: PRE-38	
MAZINDOL	Dosage form(s): TABLET	Strength(s): 1mg
	Manufacturers: SAN, W-A	
	Category: B	
MEPHOBARBITAL	Dosage form(s): TABLET	Strength(s): 32mg, 100mg, 200mg
	Manufacturers: BOW, ICN, S/W	
	Category: PRE-38	
METHENAMINE MANDELATE	Dosage form(s): SUSPENSION	Strength(s): 0.25, 0.5g/5ml
	TABLET	0.25g, 0.5g, 1g
	ENTERIC COATED TABLET	0.25g, 0.5g, 1g
	Manufacturers: GEV, HEA, ALP, P/D, RIC, SLV, TAB	
	Category: PRE-38	
METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID, METHYLENE BLUE)	Dosage form(s): TABLET	Strength(s): 40.8mg/18mg/0.03mg/ 0.03mg/4.5mg/5.4mg
	Manufacturers: CHE, LEM, , S-M, STR	
	Category: DESI	
METHYLENE BLUE	Dosage form(s): INJECTION	Strength(s): 1%
	TABLET	
	Manufacturers: ARL, CMC, ESR, TAY,	
	Category: PRE-38	
METHYLTESTOSTERONE	Dosage form(s): CAPSULE	Strength(s): 10mg
	SUBL. TABLET	10mg, 25mg
	Manufacturers: DAN, INW, LAN, PUR, SCH	

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Category:	B
MORPHINE SULFATE	
Dosage form(s):	SUSTAINED RELEASE TABLET Strength(s): 30mg, 60mg, 100mg
Manufacturers:	PUF, ROX
Category:	B
NEOSTIGMINE METHYLSULFATE	
Dosage form(s):	INJECTION Strength(s): 1-1000, 1-2000, 1-4000
Manufacturers:	CMC, ESR, LAN, S-M,
Category:	PRE-38
NITROGLYCERIN	
Dosage form(s):	SUBLINGUAL TABLET Strength(s): 0.3mg, 0.4mg, 0.6mg
Manufacturers:	P/D ETX
Category:	PRE-38
NORTRIPTYLINE HCl	
Dosage form(s):	CAPSULE Strength(s): 10mg, 25mg
Manufacturers:	LIL, SAN
Category:	B
NYLIDRIN	
Dosage form(s):	TABLET Strength(s): 6mg, 12mg
Manufacturers:	GEV, C/P, DAN, ROR, ZGP
Category:	DESI
OPIUM TINCTURE, DEODORIZED	
Dosage form(s):	LIQUID Strength(s): 10% OPIUM
Manufacturers:	HAL, LIL
Category:	PRE-38
PAPAVERINE HCl (NON-SUSTAINED RELEASE)	
Dosage form(s):	INJECTION Strength(s): 30mg/ml
	CAPSULE 75mg, 150mg, 300mg
	TABLET 30mg, 60mg, 100mg, 150mg, 200mg, 300mg
Manufacturers:	CHE, CMC, GEV, DAN, HAL, HEA, LAN, LEM, MMD, MYL, PUR, REN, SLV, VAN, EON, ZGP
Category:	PRE-38
PARALDEHYDE	
Dosage form(s):	LIQUID Strength(s): 100%
	INJECTION
Manufacturers:	CMC, ESR,
Category:	PRE-38
PAREGORIC	
Dosage form(s):	LIQUID Strength(s): 2mg MORPHINE EQUIV./5ml
Manufacturers:	APC, BOW, HAL, LAN, LIL, ALP, P/D, PUR, ROX, RPC, STL
Category:	OTC
PENICILLIN G BENZATHINE	
Dosage form(s):	INJECTION Strength(s): 600, 000 UNITS/ml
Manufacturers:	PFI, W-A
Category:	B
PENTAERYTHRITOL TETRANITRATE	
Dosage form(s):	TABLET Strength(s): 10, 20
	SUSTAINED ACTION TABLET 80mg
Manufacturers:	COO, GEV, DAN, INW, KIR, MER, P/D, PUR, STA, S-M, ZGP
Category:	DESI
PHENAZOPYRIDINE HCl	
Dosage form(s):	TABLET Strength(s): 100mg, 200mg
Manufacturers:	AMI, BAR, COP, C-P, LAN, P/D, QUA, RIC, S-M, TAB, VAN,
Category:	PRE-38
PHENOBARBITAL	
Dosage form(s):	ELIXIR Strength(s): 20mg/5ml

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

	TABLET	15mg, 16mg, 30mg, 32mg, 60mg, 65mg, 100mg
Manufacturers:	APC, BAR, BOW, GEV, C/P, DAN, HAL, ICN, INW, LAN, LED, LEM, LIL, MMD, ALP, P/D, PUR, REX, ROX, RUG, STL, STA, TAB, EON, W-W, S/W, W-A, ZGP	
Category:	PRE-38	
PHENYLEPHRINE HCl		
Dosage form(s):	SOLUTION	Strength(s): 0.25%, 1%
	OPHTHALMIC SOLUTION	0.12, 2.5, 10%
Manufacturers:	AKO, ALC, ALL, ALP, MUR, B&L, PUF, RPC, STS, S/W	
Category:	PRE-38	
PHENYLPROPANOLAMINE HCl, PHENYLEPHRINE HCl, PHENYLTOLOXAMINE CITRATE, CHLORPHENIRAMINE MALEATE		
Dosage form(s):	PEDIATRIC DROPS	Strength(s): 5mg/1.25mg/2mg/0.5mg/ml
	PEDIATRIC SYRUP	5mg/1.25mg/2mg/0.5mg/5ml
Manufacturers:	ALP, APO	
Category:	PRE-38	
PHYTONADIONE		
Dosage form(s):	INJECTION	Strength(s): 2mg, 10mg/ml
Manufacturers:	ABB, ROC, IMS, MCK, SKB	
Category:	B	
PILOCARPINE HCl		
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.25%, 0.5%, 1%, 2%, 3%, 4%, 6%, 8%
Manufacturers:	ALC, CVO, W-A, OPT, B&L, PRO, STS	
Category:	PRE-38	
PIPERAZINE CITRATE		
Dosage form(s):	SYRUP	Strength(s): 500mg/5ml
	TABLET	250mg, 500mg
Manufacturers:	BLU,ALP, GLW, LAN, SLV, S/W	
Category:	PRE-38	
POTASSIUM GLUCONATE		
Dosage form(s):	LIQUID	Strength(s): 20mEq/15ml
Manufacturers:	ALP, CMC, GEV, LAN, LED, , RAH, ROX, RPC, S-M,	
Category:	B	
POTASSIUM IODIDE		
Dosage form(s):	LIQUID	Strength(s): SATURATED SOLUTION
Manufacturers:	ALP, CMC, GEN, GEV, P/R, ROX, RPC, STL, , USL	
Category:	PRE-38	
PREDNISOLONE ACETATE		
Dosage form(s):	INJECTION	Strength(s): 25, 50, 100mg/ml
Manufacturers:	ALC, ALL, CTL, STS, LEM, B&L, SCH	
Category:	B	
PREDNISOLONE TEBUTATE		
Dosage form(s):	INJECTION	Strength(s): 20mg/ml
Manufacturers:	ALP, FOY, RBP, MCK	
Category:	B	
PROBENECID W/ COLCHICINE		
Dosage form(s):	TABLET	Strength(s): 500mg/0.5mg
Manufacturers:	DAN, LEM, MCK, RIC, ZGP	
Category:	B	
PROMETHAZINE HCl		
Dosage form(s):	TABLET	Strength(s): 12.5mg, 25mg, 50mg
Manufacturers:	ALL, ALT, ALP, DAN, ESR, GEV, KNO, KVN, LEM, LIF, MSM, RPC, S/W, W-A	
Category:	B	
PROPYLTHIOURACIL		
Dosage form(s):	TABLET	Strength(s): 50mg
Manufacturers:	ANA, KNO, CHE, DAN, LIL, HAL, LAN, LED, P/D, PUR, RIC, TAB, W-W, ZEN	

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Category:	B
PSEUDOEPHEDRINE HCl	
Dosage form(s):	LIQUID Strength(s): 30mg/5ml TABLET 30mg, 60mg SUSTAINED RELEASE CAPSULE 120mg
Manufacturers:	ALP, BOW, GLW, CEN, CHE, GEV, DAN, HAL, RBP, LEM, MMD, PAR, ROX, SLV, SUP
Category:	OTC
PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE	
Dosage form(s):	TABLET Strength(s): 60mg/4mg
Manufacturers:	BER, GLW, ROR, SCH, SKB
Category:	OTC
PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE	
Dosage form(s):	SUSTAINED RELEASE TABLET Strength(s): 120mg/6mg
Manufacturers:	COP, GEV, SCH
Category:	OTC
QUININE SULFATE	
Dosage form(s):	TABLET Strength(s): 260mg
Manufacturers:	CHE, GEV, MMD
Category:	PRE-38
RAUWOLFIA SERPENTINA	
Dosage form(s):	TABLET Strength(s): 50mg, 100mg
Manufacturers:	BOW, CMB, GEV, DAN, FER, HAL, ICN, KIR, PAN, PPI, PRI, BMS, SLV, RIC, TAB, VAL, ZEN
Category:	B
RESERPINE	
Dosage form(s):	TABLET Strength(s): 0.1mg, 0.25mg, 0.5mg, 1.0mg INJECTION
Manufacturers:	BEL, BMS, BOW, CMB, GEV, DAN, FER, GEI, GEN, HAL, ICN, , KIR, LAN, LEM, LIL, MKL, MYL, PAN, PRV, PRI, PUR, SLV, REX, RIC, ROX, STL, TAB, P/U, VAL, ZEN
Category:	B
SALSALATE	
Dosage form(s):	TABLET Strength(s): 500mg, 750mg
Manufacturers:	GEV, 3MP, SID
Category:	Pre-38
SODIUM FLUORIDE	
Dosage form(s):	TABLET Strength(s): 0.55mg, 1.1mg, 2.2mg (NaF) DROPS 0.125mg (F-)/DROP CHEWABLE TABLET 0.55mg, 1.1mg, 2.2mg (NaF)
Manufacturers:	ABL, KNO, BOW, CHE, CMC, COP, C-P, GEN, HOY, KIR, RIC, RUG, STL,
Category:	PRE-38
SULFAMETHOXAZOLE, PHENAZOPYRIDINE HCl	
Dosage form(s):	TABLET Strength(s): 500/100mg
Manufacturers:	COP, RIC
Category:	DESI
SULFASALAZINE	
Dosage form(s):	ENTERIC COATED TABLETS Strength(s): 500mg
Manufacturers:	DAN, LED, LEM, MUT, KBP, ROW, SUP, VIP
Category:	B
SULFISOXAZOLE PHENAZOPYRIDINE HCl	
Dosage form(s):	TABLET Strength(s): 500/50mg
Manufacturers:	COP, KAY, ROC, ROX, SLV, S-M, STN, VAN,
Category:	DESI
TERBUTALINE SULFATE	
Dosage form(s):	TABLET Strength(s): 2.5mg, 5mg

720.200: continued

MASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

Manufacturers:	GEI, MMD	
Category:	B	
TESTOSTERONE		
Dosage form(s):	INJECTION	Strength(s): 25mg/ml, 50mg/ml, 100mg/ml
Manufacturers:	BAT, STS,RBP, LIL, MAY	
Category:	PRE-38	
TETRACAINE HCl		
Dosage form(s):	OPHTHALMIC SOLUTION	Strength(s): 0.5%
Manufacturers:	ALC, GEN, B&L, S-M, S/W	
Category:	PRE-38	
THEOPHYLLINE (NON-SUSTAINED RELEASE)		
Dosage form(s):	CAPSULE	Strength(s): 100mg, 200mg
	TABLET	100, 125, 200, 225, 250mg
Manufacturers:	ALP, BEL, BER, CNC, CTL, FER, HAL, KNO, LAN, LIF, MMD, PAN, P/A, RIC, 3MP, ROR, ROX, RPC, SEA,	
Category:	B	
THEOPHYLLINE, GUAIFENESIN		
Dosage form(s):	ELIXIR	Strength(s): 150mg/90mg/15ml
	LIQUID	
Manufacturers:	MEA, RPC	
Category:	PRE-38	
THEOPHYLLINE, POTASSIUM IODIDE (THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)		
Dosage form(s):	ELIXIR	Strength(s): 80mg/130mg/10%/15ml
Manufacturers:	FOR, ALP, RPC	
Category:	PRE-38	
THYROGLOBULIN		
Dosage form(s):	TABLET	Strength(s): 65mg
Manufacturers:	RIC, P/D, W-L	
Category:	B	
TRIAMCINOLONE DIACETATE		
Dosage form(s):	INJECTION	Strength(s): 25mg, 40mg/ml
Manufacturers:	BMS, LED, LEM, STS	
Category:	B	
TRICHLORMETHIAZIDE, RESERPINE		
Dosage form(s):	TABLET	Strength(s): 4mg/0.1mg
Manufacturers:	MMD, SCH	
Category:	B	
TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl		
Dosage form(s):	TABLET	Strength(s): 2.5mg/60mg
	SYRUP	1.25mg/30mg/5ml
Manufacturers:	GLW, ALP, CHE, CNC, GEV, HAL, ICN, LED, LEM, LIF, NEW, B&L, PRI, PUR, ROX, SLV, SUP, VAN, ZEN	
Category:	OTC	
TRYPSIN, BALSAM PERU, CASTOR OIL		
Dosage form(s):	TOPICAL AEROSOL	Strength(s): 0.1mg/72.5mg/650mg IN EACH 0.82CC SPRAY
Manufacturers:	COP, HIC	
Category:	PRE-38	

720.200: continued

PARTIAL PROPRIETARY BRAND CROSS-REFERENCE

Generically equivalent drug products in the same strength and dosage form listed in the *Additional List* are interchangeable if their respective manufacturers are listed for that product. This partial cross-reference section does not attempt to list all brand names which are approved for interchange. For most products only one, usually the innovator or most commonly prescribed brand, is listed below for quick reference purposes.

See page 4105 for precise instructions for determining the interchangeability of drug products.

BRAND	SEE
	(ATROPINE SULFATE, HYOSCINE HBr, HYOSCYAMINE HBr, PHENOBARBITAL)
	(THEOPHYLLINE, POTASSIUM IODIDE, ALCOHOL)
ACTIFED.....	TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl
ANDROID	METHYLTESTOSTERONE
	ANTABUSE DISULFIRAM
AQUAMEPHYTON.....	PHYTONADIONE
AURALGAN	BENZOCAINE, ANTIPYRINE
AZO-GANTANOL	SULFAMETHOXAZOLE, PHENAZOPYRIDINE
AZO-GANTRISIN.....	SULFISOXAZOLE PHENAZOPYRIDINE HCl
AZULFADINE	SULFASALAZINE
BENADRYL.....	DIPHENHYDRAMINE HCl
	CYANOCOBALAMIN
BICILLIN.....	PENICILLIN G BENZATHINE
BRETHINE	TERBUTALINE SULFATE
CHLOR-TRIMETON	CHLORPHENIRAMINE MALEATE
COL-BENEMID	PROBENECID W/ COLCHICINE
	CYCLANDELATE
DECADRON	DEXAMETHASONE
DESQUAM.....	BENZOYL PEROXIDE
DIMETANE DX	BROMPHENIRAMINE, DEXTROMETHORPHAN, PSEUDOEPHEDRINE
DIUPRESS.....	CHLOROTHIAZIDE W/ RESERPINE
DONNATAL.....	ATROPINE SULFATE COMPOUND
DRAMAMINE.....	DIMENHYDRINATE
DRIXORAL	(product reformulated)
ECONOPRED.....	PREDNISOLONE ACETATE
ELIXOPHYLLINE KI	THEOPHYLLINE, POTASSIUM IODIDE
EMPIRIN W/ CODEINE	ASPIRIN W/ CODEINE PHOSPHATE
ESTINYL	ETHINYL ESTRADIOL
EXNA	BENZTHIAZIDE
FEDAHIST	PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE
GLAUCON	EPINEPHRINE HCl
GRANULEX.....	TRYPSIN, BALSAM PERU, CASTOR OIL
HALOTESTIN.....	FLUOX\YMESTERONE
HYCOMINE	HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAMINE
HYDROPRES	HYDROCHLOROTHIAZIDE W/ RESERPINE
ISOPTO CARPINE.....	PILOCARPINE HCl
ISORDIL TEMBID.....	ISOSORBIDE DINITRATE
ISUPREL	ISOPROTERENOL HCl
KAON	POTASSIUM GLUCONATE
KENALOG	TRIAMCINOLONE DIACETATE
LARODOPA.....	LEVODOPA
LEVSIN	L-HYOSCYAMINE SULFATE
LIBRAX.....	CHLORDIAZEPOXIDE W/CLIDINIUM BROMIDE
MANDELAMINE.....	METHENAMINE MANDELATE
MEBARAL	MEPHOBARBITAL
MENEST.....	ESTROGENS, ESTERIFIED

720.200: continued

BRAND	SEE
METALONE T.B.A.....	PREDNISOLONE TEBUTATE
MICRONASE	GLYBURIDE
	MAGNESIUM SALICYLATE
NEO-SYNEPHRINE	PHENYLEPHRINE HCl
	CHLORAL HYDRATE
PAMELOR.....	NORTRIPTYLINE HCl
PHENERGAN PLAIN	PROMETHAZINE HCl
PONTOCAINE	TETRACAINE HCl
PROSED	METHENAMINE COMBINATION (METHENAMINE, PHENYLSALICYLATE, ATROPINE SULFATE, HYOSCYAMINE, BENZOIC ACID METHYLENE BLUE)
PROSTIGMINE	NEOSTIGMINE METHYLSULFATE
PYRIDIUM.....	PHENAZOPYRIDINE HCl
QUINAMM.....	QUININE SULFATE
SALUTENSIN	HYDROFLUMETHIAZIDE, RESERPINE
SANOREX.....	MAZINDOL
SERAPES.....	HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE
SLO-PHYLLIN GG	THEOPHYLLINE, GUAIFENESIN
SLO-PHYLLIN	THEOPHYLLINE (NON-SUSTAINED RELEASE)
SSKI.....	POTASSIUM IODIDE
SUDAFED	PSEUDOEPHEDRINE HCl
SYNTHROID.....	LEVOTHYROXINE SODIUM
TENUATE	DIETHYLPROPION HCl
	TESTOSTERONE
TUINAL.....	AMOBARBITAL SODIUM, SECOBARBITAL SODIUM
VASODILAN	ISOXSUPRINE

(PAGES 4127 THROUGH 4132 ARE RESERVED FOR FUTURE USE.)